FDA approval

UniQure faces class action lawsuit over alleged FDA disclosure misrepresentations. Investors have until April 13, 2026 deadline to join litigation.

Law firm sues uniQure for allegedly misrepresenting gene therapy trial status and FDA approval timeline, causing stock to surge 250% then fall 49% after FDA reversal.

Artios Pharma appoints three senior executives to strengthen manufacturing, clinical operations, and medical affairs as it advances late-stage oncology trials.

uniQure faces securities lawsuit alleging misleading statements about AMT-130's FDA pathway. Stock dropped 49% after FDA reversed stance. Investors have April deadline for lead plaintiff claims.

Rosen Law Firm files securities class action against Inovio Pharmaceuticals for allegedly making false statements about manufacturing deficiencies and regulatory prospects between October 2023 and December 2025.

Rosen Law Firm sued uniQure for allegedly misleading investors about FDA approval timelines and regulatory study status between September-October 2025.

CRISPR Therapeutics eyes growth from Casgevy commercialization and pipeline expansion. FDA-approved gene therapy generates revenue while multiple clinical programs advance toward 2026 milestones.

Inovio Pharmaceuticals faces class action lawsuit for allegedly misleading investors about device manufacturing capabilities and regulatory delays, leading to 24% stock decline.

Citius Oncology reports maiden revenue of $3.9M from LYMPHIR immunotherapy launch in December 2025, marking transition to commercial-stage biopharmaceutical company.

Eli Lilly stockpiles $1.5B of experimental weight-loss drug orforglipron ahead of expected April FDA approval decision, signaling management confidence.